DBV Technologies (NASDAQ:DBVT) Shares Pass Below 50 Day Moving Average – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $17.34 and traded as low as $15.24. DBV Technologies shares last traded at $15.71, with a volume of 142,942 shares changing hands.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Citizens Jmp increased their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Guggenheim reaffirmed a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Down 1.3%

The company has a 50-day moving average of $17.34 and a 200 day moving average of $19.54. The firm has a market capitalization of $930.19 million, a PE ratio of -3.52 and a beta of -0.95.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. As a group, equities analysts anticipate that DBV Technologies S.A. will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds have recently bought and sold shares of the stock. Allworth Financial LP purchased a new position in DBV Technologies in the 4th quarter worth approximately $32,000. Royal Bank of Canada purchased a new stake in shares of DBV Technologies during the 4th quarter valued at $34,000. GAMMA Investing LLC raised its position in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares in the last quarter. Truvestments Capital LLC lifted its holdings in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after acquiring an additional 1,620 shares during the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in shares of DBV Technologies during the 4th quarter worth $115,000. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.